-
Mashup Score: 0News and Insights for Oncology Nurses | Cancer Nursing Today - 1 month(s) ago
Cancer Nursing Today strives to inform, educate, and empower oncology nurses with content that allows them to best serve their patients and reach professional success.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Eleventh SOHO Annual Meeting - 2 month(s) ago
The Eleventh Society of Hematologic Oncology Annual Meeting will be held September 6-9, 2023, in Houston, Texas. The meeting will feature presentations and sessions that focus on the latest advances in the field of hematologic oncology.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Looking for the latest news from the Eleventh Annual Meeting of the @SocietyofHemOnc? Find our coverage of key stories from #SOHO2023 here: https://t.co/1FV841n91e https://t.co/NZcUAt2YF6
-
-
Mashup Score: 0News and Insights for Oncology Nurses | Cancer Nursing Today - 3 month(s) ago
Cancer Nursing Today strives to inform, educate, and empower oncology nurses with content that allows them to best serve their patients and reach professional success.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet-
#SOHO2023 is in the books, and we've got plenty of recap coverage. Our points of focus were on GVHD, CLL, and PV, and you can read about all the most pertinent research presented on these topics here: https://t.co/eWs7Znleqp
-
-
Mashup Score: 1
This issue of Blood Cancers Today includes a feature on the wave of bispecific ant ibody approvals; a Get to Know with Jerald Radich, MD; a field dispatch on the oncology drug shortage; and
Source: bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
Looking to start your week with a great read? Catch the October issue of BCT, which includes a spotlight of #SOHO2023, a message from Associate Editor @kmaddmd, a Get to Know with Jerald Radich, MD of @fredhutch, and more! 📖 https://t.co/d9BV32LFRn https://t.co/1B9XsY4FU9
-
-
Mashup Score: 2How can we improve care for elderly patients with HL? - 7 month(s) ago
During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Jonathan Friedberg, James P. Wilmot Cancer Centre, New York, US. We asked, How can we improve care for elderly patients with HL?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📽️ The Lymphoma Hub was pleased to speak to Jonathan Friedberg Friedberg, James P. Wilmot Cancer Centre, New York, US. We asked, How can we improve care for elderly patients with HL? Click here to see what was said 👉 https://t.co/LbzcMEwahD. #SOHO23 #SOHO2023 #leusm #lymsm… https://t.co/vhMZyFLV3a
-
-
Mashup Score: 0
Naval G. Daver, MD, discusses the rationale for investigating uproleselan combinations in patients with acute myeloid leukemia, the current role of quizartinib in patients with FLT3-ITD–mutated disease, and potential future directions with both these agents in the AML field.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An ongoing phase 1 trial of uproleselan plus azacitidine and venetoclax in patients with treatment-naïve AML may add to the body of research supporting the use of the E-selectin inhibitor. @Daver_Leukemia @MDAndersonNews @SocietyofHemOnc #SOHO2023 #leusm https://t.co/8ZeV04iTwJ https://t.co/2hoUfHWByD
-
-
Mashup Score: 0Research Demonstrates the Importance of Effective Frontline Regimens for High-Risk Multiple Myeloma - 7 month(s) ago
Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma. @MSKCancerCenter @szusmani @SocietyofHemOnc #SOHO2023 #mmsm https://t.co/4bgbtuz7M7
-
-
Mashup Score: 8SOHO Keating Awardee Dr. Cortes Speaks on the Honor - 7 month(s) ago
Jorges Cortes, MD, who serves as Director of the Georgia Cancer Center in Augusta, discusses what it means for him to honored with the Michael J. Keating Award from the Society of Hematologic Oncology (SOHO) during a plenary session at the Society’s annual meeting. “It is particularly meaningful to me because it is in honor of Dr. Keating,” Dr. Cortes said. “Dr. Keating was a giant in hematologic malignancies research [and] patient care. As a resident, I was reading hi s papers and learning from him from
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
In this video interview, @GCC_Cortes of @GACancerCenter, reflects on what it meant to receive the Michael J. Keating Award from the @SocietyofHemOnc at #SOHO23. 📺https://t.co/xg39o2iusp #SOHO2023 https://t.co/o2rH9285iG
-
-
Mashup Score: 0Luspatercept Broadens Lower-Risk MDS Treatment Landscape - 7 month(s) ago
Guillermo Garcia-Manero, M, discusses key efficacy and safety findings from the COMMANDS trial; the significance of the FDA approval of luspatercept in patients with lower-risk MDS; and considerations for bringing this agent into clinical practice.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guillermo Garcia-Manero, M, discusses key efficacy and safety findings from the COMMANDS trial, the significance of the FDA approval of luspatercept in patients with lower-risk MDS, and more. @mdandersonnews #SOHO2023 #hematology https://t.co/ci3XALY5DF
-
-
Mashup Score: 0Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation - 7 month(s) ago
The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some favoring a watch-and-wait approach and others advocating for early treatment. @SocietyofHemOnc #SOHO2023 #mmsm https://t.co/QOMVlwJSou
-
#SOHO2023 is in the books, and we've got plenty of recap coverage. Our points of focus were on GVHD, CLL, and PV, and you can read about all the most pertinent research presented on these topics here: https://t.co/eWs7Znleqp